Compare EL & BNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EL | BNTX |
|---|---|---|
| Founded | 1946 | 2008 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.9B | 24.8B |
| IPO Year | 1995 | 2019 |
| Metric | EL | BNTX |
|---|---|---|
| Price | $108.57 | $98.14 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 21 | 11 |
| Target Price | $98.19 | ★ $137.40 |
| AVG Volume (30 Days) | ★ 3.1M | 1.2M |
| Earning Date | 02-03-2026 | 11-03-2025 |
| Dividend Yield | ★ 1.29% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $14,446,000,000.00 | $3,698,814,972.00 |
| Revenue This Year | $7.39 | $2.03 |
| Revenue Next Year | $4.06 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 3.70 |
| 52 Week Low | $48.37 | $81.20 |
| 52 Week High | $110.37 | $129.27 |
| Indicator | EL | BNTX |
|---|---|---|
| Relative Strength Index (RSI) | 62.78 | 58.24 |
| Support Level | $104.33 | $95.85 |
| Resistance Level | $108.50 | $95.71 |
| Average True Range (ATR) | 2.24 | 1.79 |
| MACD | -0.32 | 0.80 |
| Stochastic Oscillator | 71.94 | 87.94 |
Estée Lauder is a leader in the global prestige beauty market, participating across skin care (49% of fiscal 2025 sales), makeup (29%), fragrance (17%), and hair care and others (5%), with top-selling brands such as Estée Lauder, Clinique, M.A.C, La Mer, Jo Malone London, Aveda, Bobbi Brown, and Origins. The firm operates in more than 150 countries, generating 31% of revenue from the Americas, 37% from Europe, the Middle East and Africa (including travel retail), and 32% from Asia-Pacific. Estée Lauder sells its products through department stores, travel retail, specialty multibrand beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.